Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells

L R Sun, J L Zhong, S X Cui, X Li, Stephen G Ward, Y Q Shi, X F Zhang, Y N Cheng, J J Gao, X J Qu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

QA3 is a derivative of the substituted 1,3-dimethyl-1H-quinoxalin-2-ones, which are compounds that may selectively antagonize P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells. Our previous work identified QA3 as a candidate compound for reversing MDR in cancer cells. In the present study, we found that QA3 significantly decreases the intracellular level of ATP, stimulates ATPase activity in membrane microsomes and decreases protein kinase C (PKC) activity. These results indicated that QA3 inhibits P-gp activity by blocking ATP hydrolysis and ATP regeneration. Furthermore, QA3 triggered and increased adriamycin-induced K562/A02 cell apoptosis as evidenced by Annexin V-FITC plus PI staining. Western blot analysis showed that the levels of cleaved caspase-9 and cleaved caspase-3 proteins increased, and similarly, the levels of procaspase-9 and procaspase-3 decreased after QA3 treatment. Consequently, poly ADP-ribose polymerase (PARP) activity increased as evidenced by the presence of the PARP cleavage product in K562/A02 cells. QA3 also enhanced the potency of adriamycin against K562/A02 cells as demonstrated by increased apoptosis and activation of caspase-9,-3 and PARP. These data support the observation that P-gp activity is inhibited after QA3 treatment. Moreover, these results indicate that QA3 is a novel MDR reversal agent with potent inhibitory action against P-gp MDR cancer cells.
Original languageEnglish
Pages (from-to)333-342
Number of pages10
JournalPharmacological Reports
Volume62
Issue number2
Publication statusPublished - 2010

Fingerprint

K562 Cells
Multiple Drug Resistance
P-Glycoprotein
varespladib methyl
Doxorubicin
Poly(ADP-ribose) Polymerases
Caspase 9
Caspase 3
Adenosine Triphosphate
Apoptosis
Quinoxalines
Neoplasms
Fluorescein-5-isothiocyanate
Annexin A5
Microsomes
Protein Kinase C
Adenosine Triphosphatases
Regeneration
Hydrolysis
Western Blotting

Cite this

Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells. / Sun, L R; Zhong, J L; Cui, S X; Li, X; Ward, Stephen G; Shi, Y Q; Zhang, X F; Cheng, Y N; Gao, J J; Qu, X J.

In: Pharmacological Reports, Vol. 62, No. 2, 2010, p. 333-342.

Research output: Contribution to journalArticle

Sun, LR, Zhong, JL, Cui, SX, Li, X, Ward, SG, Shi, YQ, Zhang, XF, Cheng, YN, Gao, JJ & Qu, XJ 2010, 'Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells', Pharmacological Reports, vol. 62, no. 2, pp. 333-342.
Sun, L R ; Zhong, J L ; Cui, S X ; Li, X ; Ward, Stephen G ; Shi, Y Q ; Zhang, X F ; Cheng, Y N ; Gao, J J ; Qu, X J. / Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells. In: Pharmacological Reports. 2010 ; Vol. 62, No. 2. pp. 333-342.
@article{9639105a32bd448d8fbcad91675adacc,
title = "Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells",
abstract = "QA3 is a derivative of the substituted 1,3-dimethyl-1H-quinoxalin-2-ones, which are compounds that may selectively antagonize P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells. Our previous work identified QA3 as a candidate compound for reversing MDR in cancer cells. In the present study, we found that QA3 significantly decreases the intracellular level of ATP, stimulates ATPase activity in membrane microsomes and decreases protein kinase C (PKC) activity. These results indicated that QA3 inhibits P-gp activity by blocking ATP hydrolysis and ATP regeneration. Furthermore, QA3 triggered and increased adriamycin-induced K562/A02 cell apoptosis as evidenced by Annexin V-FITC plus PI staining. Western blot analysis showed that the levels of cleaved caspase-9 and cleaved caspase-3 proteins increased, and similarly, the levels of procaspase-9 and procaspase-3 decreased after QA3 treatment. Consequently, poly ADP-ribose polymerase (PARP) activity increased as evidenced by the presence of the PARP cleavage product in K562/A02 cells. QA3 also enhanced the potency of adriamycin against K562/A02 cells as demonstrated by increased apoptosis and activation of caspase-9,-3 and PARP. These data support the observation that P-gp activity is inhibited after QA3 treatment. Moreover, these results indicate that QA3 is a novel MDR reversal agent with potent inhibitory action against P-gp MDR cancer cells.",
author = "Sun, {L R} and Zhong, {J L} and Cui, {S X} and X Li and Ward, {Stephen G} and Shi, {Y Q} and Zhang, {X F} and Cheng, {Y N} and Gao, {J J} and Qu, {X J}",
year = "2010",
language = "English",
volume = "62",
pages = "333--342",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "2",

}

TY - JOUR

T1 - Modulation of P-glycoprotein activity by the substituted quinoxalinone compound QA3 in adriamycin-resistant K562/A02 cells

AU - Sun, L R

AU - Zhong, J L

AU - Cui, S X

AU - Li, X

AU - Ward, Stephen G

AU - Shi, Y Q

AU - Zhang, X F

AU - Cheng, Y N

AU - Gao, J J

AU - Qu, X J

PY - 2010

Y1 - 2010

N2 - QA3 is a derivative of the substituted 1,3-dimethyl-1H-quinoxalin-2-ones, which are compounds that may selectively antagonize P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells. Our previous work identified QA3 as a candidate compound for reversing MDR in cancer cells. In the present study, we found that QA3 significantly decreases the intracellular level of ATP, stimulates ATPase activity in membrane microsomes and decreases protein kinase C (PKC) activity. These results indicated that QA3 inhibits P-gp activity by blocking ATP hydrolysis and ATP regeneration. Furthermore, QA3 triggered and increased adriamycin-induced K562/A02 cell apoptosis as evidenced by Annexin V-FITC plus PI staining. Western blot analysis showed that the levels of cleaved caspase-9 and cleaved caspase-3 proteins increased, and similarly, the levels of procaspase-9 and procaspase-3 decreased after QA3 treatment. Consequently, poly ADP-ribose polymerase (PARP) activity increased as evidenced by the presence of the PARP cleavage product in K562/A02 cells. QA3 also enhanced the potency of adriamycin against K562/A02 cells as demonstrated by increased apoptosis and activation of caspase-9,-3 and PARP. These data support the observation that P-gp activity is inhibited after QA3 treatment. Moreover, these results indicate that QA3 is a novel MDR reversal agent with potent inhibitory action against P-gp MDR cancer cells.

AB - QA3 is a derivative of the substituted 1,3-dimethyl-1H-quinoxalin-2-ones, which are compounds that may selectively antagonize P-glycoprotein (P-gp) in multidrug resistance (MDR) cancer cells. Our previous work identified QA3 as a candidate compound for reversing MDR in cancer cells. In the present study, we found that QA3 significantly decreases the intracellular level of ATP, stimulates ATPase activity in membrane microsomes and decreases protein kinase C (PKC) activity. These results indicated that QA3 inhibits P-gp activity by blocking ATP hydrolysis and ATP regeneration. Furthermore, QA3 triggered and increased adriamycin-induced K562/A02 cell apoptosis as evidenced by Annexin V-FITC plus PI staining. Western blot analysis showed that the levels of cleaved caspase-9 and cleaved caspase-3 proteins increased, and similarly, the levels of procaspase-9 and procaspase-3 decreased after QA3 treatment. Consequently, poly ADP-ribose polymerase (PARP) activity increased as evidenced by the presence of the PARP cleavage product in K562/A02 cells. QA3 also enhanced the potency of adriamycin against K562/A02 cells as demonstrated by increased apoptosis and activation of caspase-9,-3 and PARP. These data support the observation that P-gp activity is inhibited after QA3 treatment. Moreover, these results indicate that QA3 is a novel MDR reversal agent with potent inhibitory action against P-gp MDR cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=77953328108&partnerID=8YFLogxK

UR - http://www.if-pan.krakow.pl/pjp/cont10.html#No2

M3 - Article

VL - 62

SP - 333

EP - 342

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 2

ER -